uploads///Duodopa

AbbVie’s Duodopa, Creon, Synagis, Synthroid, and Sevoflurane

By

Apr. 18 2018, Updated 7:31 a.m. ET

Duodopa revenue trends

In 4Q17, AbbVie’s (ABBV) Duodopa generated revenue of $100 million, marking ~28% growth YoY (year-over-year) and 6% growth quarter-over-quarter. In US and international markets, Duodopa saw revenue of $17 million and $77 million, respectively, reflecting ~55.2% and ~23% growth YoY.

In fiscal 2017, Duodopa generated revenue of $355 million, representing ~21.1% YoY growth. In 2017, in US and international markets, Duodopa generated revenue $61 million and $294 million, respectively, reflecting ~66% and 14.6% YoY growth.

Article continues below advertisement

Creon, Synagis, and Synthroid revenue trends

In 4Q17, Creon generated revenue of $235 million, reflecting ~10% YoY growth. In fiscal 2017, Creon saw revenue of $831 million, representing ~13.9% YoY growth. Creon (pancrelipase) is used for the treatment of individuals who are unable to digest food normally due to the inability of their pancreas to make enough enzymes.

In 4Q17 and fiscal 2017, Synagis reported revenue of $282 million and $738 million, respectively. Synagis (palivizumab) is used for the prevention of serious lower respiratory tract disease due to respiratory syncytial virus infection in pediatrics.

In 4Q17 and 2017, Synthroid saw revenue of $205 million and $781 million, respectively. Synthroid is used for the treatment of hypothyroidism.

Sevoflurane revenue trends

In 4Q17, Sevoflurane reported revenue of $99 million, representing a ~1.5% YoY decline. In 4Q17, in US and international markets, Sevoflurane generated revenue of $22 million and $77 million, respectively, reflecting ~1.3% and 1.6% YoY decline.

In fiscal 2017, Sevoflurane generated revenue of $410 million, representing a ~4.1% decline YoY. In 2017, in US and international markets, Sevoflurane generated revenue of $78 million and $332 million, respectively, representing a ~2.1% and 4.6% YoY decline.

HCV portfolio revenue trends

AbbVie’s anti-HCV (hepatitis C virus) portfolio includes Viekira, Technivie, and Mavyret. In 4Q17, AbbVie’s HCV drugs generated revenue of $510 million, comprising $214 million and $296 million from US and international markets, respectively.

In fiscal 2017, AbbVie’s HCV drugs saw revenue of $1.3 billion, comprising $338 million and $936 million from US and international markets, respectively. In the HCV drug market, AbbVie’s HCV drugs compete with Bristol-Myers Squibb’s (BMY) Daklinza, Merck’s (MRK) Zepatier, and Gilead Sciences’ (GILD) Epclusa.

Advertisement

More From Market Realist

  • CONNECT with Market Realist
  • Link to Facebook
  • Link to Twitter
  • Link to Instagram
  • Link to Email Subscribe
Market Realist Logo
Do Not Sell My Personal Information

© Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.